 |
9 Diseases |  |
1 Trial |
|
1 Trial |  |
304 News |  |
| «123 |
- |||| crenezumab (MABT5102A) / Roche
Trial completion date, Trial primary completion date: CREAD: A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). (clinicaltrials.gov) - Mar 8, 2019
P3, N=813, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2021 --> May 2019 | Trial primary completion date: Aug 2020 --> May 2019
- | crenezumab (MABT5102A) / Roche
Trial completion date: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Mar 6, 2019
P1, N=77, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: Jul 2021 --> May 2019 | Trial primary completion date: Aug 2020 --> May 2019 Trial completion date: Sep 2023 --> Mar 2019
- | crenezumab (MABT5102A) / Roche
Trial completion date, Trial primary completion date: CREAD OLE: An Open-Label Crenezumab Study in Participants With Alzheimer's Disease (clinicaltrials.gov) - Oct 17, 2018
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2023 --> Mar 2019 Trial completion date: Nov 2023 --> Nov 2022 | Trial primary completion date: Nov 2023 --> Nov 2022
- |||||||||| crenezumab (MABT5102A) / Roche
New P3 trial: CREAD OLE: An Open-Label Crenezumab Study in Participants With Alzheimer's Disease (clinicaltrials.gov) - Apr 9, 2018
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| crenezumab (MABT5102A) / Roche
Enrollment closed: CREAD: A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). (clinicaltrials.gov) - Jan 19, 2018
P3, N=813, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2023 --> Nov 2022 | Trial primary completion date: Nov 2023 --> Nov 2022 Recruiting --> Active, not recruiting
- || crenezumab (MABT5102A) / Roche
Preclinical, Trial primary completion date: API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - Dec 28, 2017
P2, N=252, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2020 --> Feb 2022
- || crenezumab (MABT5102A) / Roche
Enrollment closed: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Oct 18, 2017
P1, N=77, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2020 --> Feb 2022 Completed --> Active, not recruiting
- ||| crenezumab (MABT5102A) / Roche
Trial completion, Trial primary completion date: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Jul 26, 2017
P1, N=77, Completed, Sponsor: Genentech, Inc.
Completed --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2023 --> Nov 2016
- || crenezumab (MABT5102A) / Roche
Trial primary completion date: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Jul 7, 2017
P1, N=72, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jun 2023 --> Nov 2016 Trial primary completion date: May 2017 --> Jun 2023
- crenezumab (RG7412) / Roche
Trial primary completion date: A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers (clinicaltrials.gov) - May 30, 2017
P1, N=22, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: May 2017 --> Jun 2023 Trial primary completion date: Nov 2009 --> Feb 2010
- |||| crenezumab (MABT5102A) / Roche
Trial completion: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Apr 28, 2017
P2, N=360, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Nov 2009 --> Feb 2010 Active, not recruiting --> Completed
- |||||||||| crenezumab (MABT5102A) / Roche
New P3 trial: CREAD 2: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) (clinicaltrials.gov) - Apr 14, 2017
P3, N=750, Recruiting, Sponsor: Hoffmann-La Roche
- ||| crenezumab (MABT5102A) / Roche
Enrollment closed, Preclinical: API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - Apr 13, 2017
P2, N=300, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || crenezumab (MABT5102A) / Roche
Enrollment closed: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Mar 20, 2017
P1, N=72, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| crenezumab (RG7412) / Roche
Trial completion: A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose (clinicaltrials.gov) - Mar 10, 2016
P1, N=60, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| crenezumab (MABT5102A) / Roche
Enrollment closed, Trial primary completion date: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Feb 3, 2016
P2, N=360, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Completed --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Feb 2017
- |||||||||| crenezumab (MABT5102A) / Roche
New P3 trial: CREAD: A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). (clinicaltrials.gov) - Feb 1, 2016
P3, N=750, Recruiting, Sponsor: Hoffmann-La Roche
- || crenezumab (MABT5102A) / Roche
Trial primary completion date: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Jan 17, 2016
P1, N=72, Recruiting, Sponsor: Genentech, Inc.
Completed --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Feb 2017 Trial primary completion date: Sep 2015 --> May 2017
- |||| crenezumab (MABT5102A) / Roche
Trial completion, Trial primary completion date: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Dec 5, 2015
P2, N=360, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2015 --> May 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Nov 2015
- crenezumab (RG7412) / Roche
Enrollment closed: A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose (clinicaltrials.gov) - May 27, 2015
P1, N=60, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Nov 2015 Recruiting --> Active, not recruiting
- crenezumab (MABT5102A) / Roche
Enrollment change: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - May 6, 2015
P1, N=72, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting N=24 --> 72
- crenezumab (RG7412) / Roche
New P1 trial: A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose (clinicaltrials.gov) - Apr 27, 2015
P1, N=60, Recruiting, Sponsor: Genentech, Inc.
- crenezumab (MABT5102A) / Roche
Trial primary completion date: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Feb 5, 2015
P2, N=360, Active, not recruiting, Sponsor: Genentech, Inc.
N=24 --> 72 Trial primary completion date: May 2016 --> May 2017
- crenezumab (MABT5102A) / Roche
New P1 trial: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (clinicaltrials.gov) - Feb 3, 2015
P1, N=24, Recruiting, Sponsor: Genentech, Inc.
- || crenezumab (MABT5102A) / Roche
Trial primary completion date: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Sep 16, 2014
P2, N=360, Active, not recruiting, Sponsor: Genentech
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Sep 2016 --> May 2016
- || crenezumab (MABT5102A) / Roche
Trial primary completion date: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Jul 17, 2014
P2, N=360, Active, not recruiting, Sponsor: Genentech
Trial primary completion date: Sep 2016 --> May 2016 Trial primary completion date: May 2016 --> Sep 2016
- ||| crenezumab (MABT5102A) / Roche
Enrollment closed: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Jun 1, 2014
P2, N=361, Active, not recruiting, Sponsor: Genentech
Trial primary completion date: May 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- |||| crenezumab (MABT5102A) / Roche
Biomarker, Trial completion: BLAZE: A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Apr 20, 2014
P2, N=91, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| crenezumab (MABT5102A) / Roche
Trial completion: A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY) (clinicaltrials.gov) - Mar 9, 2014
P2, N=450, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| crenezumab (MABT5102A) / Roche
New P2 trial, Preclinical: API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - Nov 28, 2013
P2, N=300, Recruiting, Sponsor: Genentech
- ||| crenezumab (MABT5102A) / Roche
Biomarker, Enrollment change: BLAZE: A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - May 21, 2013
P2, N=91, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=72 --> 91
- ||| crenezumab (MABT5102A) / Roche
Enrollment change: A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY) (clinicaltrials.gov) - May 21, 2013
P2, N=450, Completed, Sponsor: Genentech
N=72 --> 91 N=372 --> 450
- |||| crenezumab (MABT5102A) / Roche
Enrollment open: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Dec 4, 2012
P2, N=400, Recruiting, Sponsor: Genentech
N=372 --> 450 Not yet recruiting --> Recruiting
- ||||| crenezumab (MABT5102A) / Roche
New P2 trial: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab (clinicaltrials.gov) - Nov 6, 2012
P2, N=400, Recruiting, Sponsor: Genentech